Technology Agnostic, Methodologically Complete

The unique needs for oncology diagnostics are evolving as quickly as our understanding of these diseases. At Cancer Genetics, we know that clinicians, patients, and their families rely on us to provide the most advanced testing available. For that reason, we offer testing across a number of technology platforms, and ensure that all of the most relevant tests are available to our customers.

Through our CLIA-certified, CAP-accredited clinical laboratory, we offer comprehensive testing for both solid tumor and hematological cancers. We utilize an expansive range of tests and technologies to provide the most comprehensive profile for each patient we serve.

Jump to test: ALL | AML | ALCL | CLL/SLL | CML | DLBCL | Lymphoma | MM | MDS | MPN | Non-CML MPN


Hematological Malignancies

»Acute Lymphocytic Leukemia (ALL)

MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood, bone marrow or disaggregated tissue at room temp.
Clinical IndicationsFor the diagnosis and prognosis of acute lymphocytic leukemia (ALL).
CPT Codes88271(13); 88275(6); 88291
TAT3-5 days

  • 11q23 (MLL-Break Apart)
  • t(9;22) (BCR/ABL/ASS)
  • 17p13 (TP53)
  • t(12;21) (ETV6/RUNX1)
  • 9p21 (CDKN2A[p16])
  • CEP4,10, 17

MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood, bone marrow or disaggregated tissue at room temp.
Clinical IndicationsFor the diagnosis and prognosis of acute lymphocytic leukemia (ALL).
CPT Codes88271(2); 88275; 88291
TAT3-5 days

  • 14q11 (TCR-Alpha/Delta Break Apart)


»Acute Myeloid Leukemia (AML)

MethodologyPCR, sequencing
Analytical Sensitivity20%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of patients with acute myeloid leukemia (AML).
CPT Codes81272
TAT7-10 days
MethodologyPCR, sequencing
Analytical Sensitivity20%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of patients with acute myeloid leukemia (AML).
CPT Codes81218
TAT7-10 days
MethodologyPCR, sequencing
Analytical Sensitivity10%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis and clinical management of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
CPT Codes81245
TAT7-10 days
MethodologySanger Sequencing
Specimen RequirementsOne unbaked, unstained 4 μm section and ten unbaked, unstained 10 μm sections on positively charged glass slides or FFPE tissue block at room temperature.
Clinical IndicationsFor the diagnosis and prognosis of glioma and the prognosis and risk stratification of acute myeloid leukemia (AML).
CPT Codes81403x2
TAT5-7 days
MethodologyPCR, sequencing
Analytical Sensitivity5%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of patients with acute myeloid leukemia (AML).
CPT Codes81310
TAT7-10 days
MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis, subtyping and prognostic stratification of acute myeloid leukemia (AML) patients.
CPT Codes88271(8); 88275(4); 88291
TAT3-5 days

  • 11q23 (MLL-Break Apart)
  • t(8;21) (ETO/AML1) [M2]
  • t(15;17) (PML/RARA) [M3]
  • inv(16) (CBFB-Break Apart) [M4, Eos]


»Anaplastic Large Cell Lymphoma (ALCL)

MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood, bone marrow or disaggregated tissue at room temp.
Clinical IndicationsFor the prognosis of anaplastic large cell lymphoma (ALCL).
CPT Codes88271(2); 88275; 88291
TAT3-5 days

  • 2p23 (ALK-Break Apart)


»Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

CGI CLL Complete

MethodologyPCR, sequencing
Analytical Sensitivity10%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis and clinical management of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
CPT Codes81263
TAT7-10 days
Mature B-cell neoplasms exhibit clonal genomic alterations that have diagnostic and prognostic significance. Once such type of alteration is gain or loss of genomic loci, which in the current test is assayed by array-comparative genomic hybridization (array-CGH) permitting the simultaneous detection of gain and loss at multiple loci. Loci being assessed by MatBA®-CLL/SLL are 1p, 2p, 3q, 4q, 5p, 6q, 7p, 7q, 8p, 8q, 11q (ATM), 12q, 13 (MIR15A/16-1), 17p (TP53), 17q, 18p, 18q, and 19p.
MethodologyArray-CGH
Analytical Sensitivity30-40%
Specimen Requirements1 Lavender/EDTA tube peripheral blood or bone marrow aspirate with minimum 2-3ml or 3-5 FFPE sections at 10 μm thickness on regular slides at room temp.
Clinical IndicationsFor the risk stratification and prognosis of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
CPT Codes81479
TAT10-14 days
Mutational NOTCH1 activation in CLL diagnosis is an independent predictor of poor survival and a shorter time to progression.
MethodologyPCR, bi-directional sequencing
Analytical Sensitivity20%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
CPT Codes81479
TAT7-10 days
MethodologyPCR, bi-directional sequencing
Analytical Sensitivity25%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL).
CPT Codes81405
TAT7-10 days
MethodologyG-banding
Specimen Requirements1 Green/NaHeparin tube (3-5 ml) peripheral blood or bone marrow at room temp.
CPT Codes88237; 88262; 88280; 88291
TAT5-7 days
MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis and prognosis of chronic lymphocytic leukemia (CLL).
CPT Codes88271(9); 88275(4); 88291
TAT3-5 days

  • 11q22.3 (ATM)/17p13 (TP53)
  • CEP12/13q14 (D13S319)/13q34
  • CEP6/6q23 (c-MYB)
  • t(11;14)(CCND1/IGH)

Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (2 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the prognosis of chronic lymphocytic leukemia (CLL).
CPT Codes88184; 88185 (x4); 88187
TAT1-2 days
MethodologyFlow cytometry
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (2 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the prognosis of chronic lymphocytic leukemia (CLL).
CPT Codes88184 or 88185; 88187
TAT1-2 days
The Focus::CLL™ NGS panel assists in the prognosis of CLL/SLL patients. Multiplexed sequencing by synthesis is performed using the MiSeq System (Illumina). This panel includes selected exons of the TP53, NOTCH1, SF3B1, BIRC3, ATM, MYD88, and Card11 genes.
MethodologyNext Generation Sequencing
Analytical Sensitivity5%
Specimen RequirementsOne Lavender (EDTA) tube of peripheral blood or bone marrow aspirate. Minimum: 2-3 mL. Shipped at room temperature.
Clinical IndicationsFor the risk stratification and prognosis of Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
CPT Codes81450
TAT10-14 days
SF3B1 mutations are independent predictors that occur in 10-15% of CLL patients. They are indicative of shorter time to treatment, and a poorer overall survival.
MethodologyPCR, bi-directional sequencing
Analytical Sensitivity20%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of chronic lymphocytic leukemia (CLL).
CPT Codes81479
TAT7-10 days


»Chronic Myeloid Leukemia (CML)

MethodologyPCR, sequencing
Analytical Sensitivity20%
Specimen Requirements1 Lavender/EDTA tube peripheral blood or bone marrow (3-5 ml) at room temp. or 2-8°C within 48 hours after collection.
Clinical IndicationsFor monitoring patients with chronic myeloid leukemia (CML).
CPT Codes81170
TAT7-10 days
Methodologyreal time PCR
Analytical Sensitivity1 tumor cell/100,000 normal cells
Specimen Requirements1 Lavender/EDTA tube PB or BM (3-5 ml) shipped at room temperature.
Clinical IndicationsThis assay utilizes quantitative PCR to diagnose CML as well as monitor CML patients for therapeutic response, minimal residual disease (MRD), and early relapse.
CPT Codes81206 (major); 81207 (minor)
TAT3-5 days
MethodologyReal-time PCR
Analytical Sensitivity1 tumor cell/ 100,000 normal cells
Specimen Requirements1 Lavender/EDTA tube peripheral blood or bone marrow (3-5 ml) at room temp. or 2-8°C within 48 hours after collection.
Clinical IndicationsFor monitoring patients with acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML).
CPT Codes81206 (major); 81207 (minor)
TAT3-5 days
MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis of chronic myelogenous leukemia (CML).
CPT Codes88271(3); 88275(1); 88291
TAT3-5 days

  • t(9;22) (BCR/ABL/ASS)

MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis of chronic myelogenous leukemia (CML).
CPT Codes88271(5); 88275(3); 88291
TAT3-5 days

  • t(9;22) (BCR/ABL/ASS)
  • 17p13 (TP53)
  • CEP8


»Diffuse Large B-Cell Lymphoma (DLBCL)

CGI DLBCL Complete

Specimen RequirementsFFPE tissue block at room temp. or 0.5 cm3 fresh tissue in RPMI on dry ice
TAT2-4 days
MethodologyIHC
Specimen RequirementsFFPE tissue block at room temp. or 0.5 cm3 fresh tissue in RPMI on dry ice
CPT Codes88342
TAT2-4 days
MethodologyIHC
Specimen RequirementsFFPE tissue block at room temp. or 0.5 cm3 fresh tissue in RPMI on dry ice
CPT Codes88342
TAT2-4 days
MethodologyIHC
Specimen RequirementsFFPE tissue block at room temp. or 0.5 cm3 fresh tissue in RPMI on dry ice
CPT Codes88342
TAT2-4 days
MethodologyIHC
Specimen RequirementsFFPE tissue block at room temp. or 0.5 cm3 fresh tissue in RPMI on dry ice
CPT Codes88342
TAT2-4 days
The lymphoid panel determines expression levels of cell surface antigens by flow cytometry that provide diagnostic information for the diagnosis and for monitoring therapy. This panel includes CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22, CD23, CD33, CD34, CD38, CD45, CD56, CD57, CD64, CD71, CD117, HLA-DR, sKappa, sLambda.
MethodologyFlow cytometry
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (2 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis of leukemia and lymphoma and for post-treatment follow-up.
CPT Codes88184; 88185 (x17); 88189
TAT1-2 days
MethodologyArray-CGH
Analytical SensitivityFFPE: 60-70%
Fresh-Frozen tissue: 50-60%"
Specimen Requirements"FFPE block: containing ≥ 70% tumor. Minimum size: 2 mm x 2 mm tumor area, shipped at room temperature.
Fresh-Frozen tissue: 0.2 cm3 min. (in OCT is acceptable) containing ≥ 50% tumor. Stored at -80°C /-20°C, shipped on dry ice.
FFPE block or fresh-frozen specimen: incisional or excisional biopsy."
Clinical IndicationsFor the risk stratification and prognosis of diffuse large B-cell lymphoma (DLBCL).
CPT Codes81479
TAT10-14 days
The presence of a TP53 mutation is associated with shorter survival and resistance to chemotherapy.
MethodologyPCR, bi-directional sequencing
Analytical Sensitivity25%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL).
CPT Codes81405
TAT7-10 days
MethodologyPCR, fragment analysis
Analytical Sensitivity1-3%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C or 30-50 μm total FFPE sections at room temp.
Clinical IndicationsFor the diagnosis of lymphomas.
CPT Codes81261
TAT7-10 days
MethodologyG-banding
Specimen Requirements1 Green/NaHeparin tube (3-5 ml) peripheral blood or bone marrow at room temp.
CPT Codes88237; 88262; 88280; 88291
TAT5-7 days
FISH analysis provides high sensitivity information about key genomic alterations and prognostic markers, such as the loss of 17p (TP53), 11q (ATM), 13q, and 6q, along with the gain of chromosome 12. The translocation t(11;14) is also evaluated to rule out Mantle Cell Lymphoma.
MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis and prognosis of chronic lymphocytic leukemia (CLL).
CPT Codes88271(9); 88275(5); 88291
TAT3-5 days


»Lymphoma

MethodologyPCR, fragment analysis
Analytical Sensitivity1-3%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C or 30-50 μm total FFPE sections at room temp.
Clinical IndicationsFor the diagnosis of lymphomas.
CPT Codes81261
TAT7-10 days
MethodologyPCR, Pyrosequencing
Analytical Sensitivity6%
Specimen RequirementsFFPE Block or 3-5 FFPE sections at 10 μm thickness containing at least 20% of tumor cells on regular unstained slides at room temp. with H&E slides.
Clinical IndicationsFor the clinical management of patients with colorectal cancer (CRC), hairy cell leukemia (HCL), melanoma, thyroid cancer
CPT Codes81210
TAT5-7 days
MethodologyArray-CGH
Analytical SensitivityFFPE: 60-70%
Fresh-Frozen tissue: 50-60%"
Specimen Requirements"FFPE block: containing ≥ 70% tumor. Minimum size: 2 mm x 2 mm tumor area, shipped at room temperature.
Fresh-Frozen tissue: 0.2 cm3 min. (in OCT is acceptable) containing ≥ 50% tumor. Stored at -80°C /-20°C, shipped on dry ice.
FFPE block or fresh-frozen specimen: incisional or excisional biopsy."
Clinical IndicationsFor the risk stratification and prognosis of diffuse large B-cell lymphoma (DLBCL).
CPT Codes81479
TAT10-14 days
MethodologyArray-CGH
Analytical Sensitivity50-60%
Specimen RequirementsFFPE block: containing ≥ 60% tumor. Minimum size: 2 mm x 2 mm tumor area, shipped at room temperature.
Fresh-Frozen tissue: 0.2 cm3 minimum (in OCT is acceptable) containing ≥50% tumor. Stored at -80°C /-20°C, shipped on dry ice.
FFPE block or fresh-frozen specimen from incisional or excisional biopsy.
Clinical IndicationsAssists in the prognosis of follicular lymphoma (FL)
CPT Codes81479
TAT10-14 days
MethodologyArray-CGH
Analytical SensitivityFFPE: 60-70%
Fresh-frozen: 50-60%
Peripheral blood: 30-40%
Specimen RequirementsFFPE block: containing ≥ 60% tumor. Minimum size: 2 mm x 2 mm tumor area, shipped at room temperature.
Fresh-Frozen tissue: 0.2 cm3 minimum (in OCT is acceptable) containing ≥50% tumor. Stored at -80°C /-20°C, shipped on dry ice.
Peripheral blood: Minimum 3-5 ml, shipped at room temperature.
Clinical IndicationsMCL
CPT Codes81479
TAT10-14 days
MethodologyPCR, pyrosequencing
Analytical Sensitivity5%
Specimen Requirements2-3 ml peripheral blood or bone marrow in an EDTA tube (Lavender-top). Specimen should be stored, transported at room temperature or 2-8°C.
Clinical IndicationsLymphoma
CPT Codes81479
TAT5-7 days
Mutational NOTCH1 activation in CLL diagnosis is an independent predictor of poor survival and a shorter time to progression.
MethodologyPCR, bi-directional sequencing
Analytical Sensitivity20%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
CPT Codes81479
TAT7-10 days
The presence of a TP53 mutation is associated with shorter survival and resistance to chemotherapy.
MethodologyPCR, bi-directional sequencing
Analytical Sensitivity25%
Specimen Requirements1 Lavender/EDTA tube peripheral blood or bone marrow (3-5 ml) at room temp. or 2-8°C within 48 hours after collection.
Clinical IndicationsFor the prognosis of breast cancer, chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL).
CPT Codes81405
TAT7-10 days
MethodologyPCR, fragment analysis
Analytical Sensitivity1-3%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C or 30-50 μm total FFPE sections at room temp.
Clinical IndicationsFor the diagnosis of lymphoma.
CPT Codes81340
TAT7-10 days
MethodologyPCR, fragment analysis
Analytical Sensitivity1-3%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C or 30-50 μm total FFPE sections at room temp.
Clinical IndicationsFor the diagnosis of lymphoma.
CPT Codes81342
TAT7-10 days
MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood, bone marrow or disaggregated tissue at room temp.
Clinical IndicationsFor the diagnosis and prognosis of non-Hodgkin lymphoma (NHL).
CPT Codes88271(11); 88275(5); 88291
TAT3-5 days

  • Burkitt: t(8;14) (MYC/IGH)
  • DLBCL: 3q27 (BCL6-Break Apart)
  • Follicular: t(14;18) (IGH/BCL2)
  • Mantle: t(11;14) (CCND1/IGH)
  • MALT Lymphoma: MALT1-Break Apart

Detection of hyper-mutation in the IGHV gene serves as an independent prognostic marker. Patients with the hyper-mutated IGHV gene exhibit a better overall survival than those with un-mutated IGHV. Utilization of IGHV3-21 regardless of IGHV mutation status is associated with an unfavorable outcome.
MethodologyPCR, sequencing
Analytical Sensitivity10%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis and clinical management of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
CPT Codes81263
TAT7-10 days


»Multiple Myeloma (MM)

MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis and prognosis of multiple myeloma.
CPT Codes88271(15); 88275(7); 88291
TAT7-10 days

  • 13q14/13q34
  • 17/17p13 (TP53)
  • 1p/1q
  • D5S23/D5S72/CEP9/CEP15
  • t(4;14) (FGFR3/IGH)
  • t(11;14) (CCND1/IGH)
  • t(14;16) (lGH/MAF)


»Myelodysplastic Syndrome (MDS)

MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis, prognosis, monitoring of response to therapy or progression of disease of myelodysplastic syndrome (MDS).
CPT Codes88271(8); 88275(4); 88291
TAT3-5 days

  • 5q15.2/5q31
  • CEP7/7q31
  • CEP8
  • 20q12
  • 11q23 (MLL-Break Apart)


»Myeloproliferative Disease (MPD)

MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis of myeloproliferative disease (MPD) or for monitoring response to therapy or progression of the disease.
CPT Codes88271(4); 88275(2); 88291
TAT3-5 days


»Myeloproliferative Neoplasm (MPN)

CGI MPN Complete

MethodologyImmunohistochemistry (IHC)
Specimen Requirements4-5μm thick FFPE sections on positively coated slides at room temp.
CPT Codes88342
TAT2-4 days
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (2 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis of leukemia, lymphoma, plasma cell neoplasms, and evaluation of myeloid maturation.
CPT Codes"Myeloid/Lymphoid: 88184; 88185 (x28); 88189
With Acute Add-On: 88184; 88185(x34); 88189"
TAT1-2 days
MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis of myeloproliferative disease (MPD) or for monitoring response to therapy or progression of the disease.
CPT Codes88271(4); 88275(2); 88291
TAT3-5 days

  • 4q12 (FIP1L1/CHIC2/PDGFRA)
  • 5q33 (PDGFRB-Break Apart)
  • BCR/ABL (BCR/ABL/ASS)
  • CEP8/CEP9

MethodologyReal-time PCR
Analytical Sensitivity1 tumor cell/ 100,000 normal cells
Specimen Requirements1 Lavender/EDTA tube peripheral blood or bone marrow (3-5 ml) at room temp. or 2-8°C within 48 hours after collection.
Clinical IndicationsFor the diagnosis of acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML).
CPT Codes81206, 81207
TAT3-5 days
MethodologyPCR, sequencing
Analytical Sensitivity1%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the diagnosis of patients with myeloproliferative neoplasms (MPN).
CPT Codes81270
TAT3-5 days
MethodologyPCR, sequencing
Analytical Sensitivity20%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the diagnosis of patients with myeloproliferative neoplasms (MPN).
CPT Codes81403
TAT7-10 days
MethodologyPCR, bi-directional sequencing
Analytical Sensitivity20%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the diagnosis of patients with myeloproliferative neoplasms (MPN).
CPT Codes81403
TAT7-10 days
MethodologyPCR, sequencing
Analytical Sensitivity0.25%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of patients with myeloproliferative neoplasms (MPN).
CPT Codes81273
TAT7-10 days
MethodologyPCR, bi-directional sequencing
Analytical Sensitivity10%
Specimen Requirements2-3 ml peripheral blood or bone marrow in an EDTA tube (Lavender-top). Specimen should be stored, transported at room temperature or 2-8°C.
Clinical IndicationsET, PMF
CPT Codes81219
TAT5-7 days


»Non-CML Myeloproliferative Neoplasm (Non-CML MPN)

MethodologyPCR, bi-directional sequencing
Analytical Sensitivity10%
Specimen Requirements2-3 ml peripheral blood or bone marrow in an EDTA tube (Lavender-top). Specimen should be stored, transported at room temperature or 2-8°C.
Clinical IndicationsET, PMF
CPT Codes81219
TAT5-7 days
MethodologyPCR, sequencing
Analytical Sensitivity0.25%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of patients with myeloproliferative neoplasms (MPN).
CPT Codes81273
TAT7-10 days
MethodologyPCR, sequencing
Analytical Sensitivity1%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the diagnosis of patients with myeloproliferative neoplasms (MPN).
CPT Codes81270
TAT3-5 days
MethodologyPCR, sequencing
Analytical Sensitivity20%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the diagnosis of patients with myeloproliferative neoplasms (MPN).
CPT Codes81403
TAT7-10 days
MethodologyPCR, bi-directional sequencing
Analytical Sensitivity20%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the diagnosis of patients with myeloproliferative neoplasms (MPN).
CPT Codes81403
TAT7-10 days
MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis of myeloproliferative disease (MPD) or for monitoring response to therapy or progression of the disease.
CPT Codes88271(4); 88275(2); 88291
TAT3-5 days

  • 4q12 (FIP1L1/CHIC2/PDGFRA)
  • 5q33 (PDGFRB-Break Apart)
  • BCR/ABL (BCR/ABL/ASS)
  • CEP8/CEP9


return to top